Development of MCT4-targeting small molecule inhibitors for management of castration-resistant prostate cancer

Late-stage, therapy-resistant prostate cancer (PCa) remains a difficult-to-treat disease that urgently needs better therapeutics. Advanced PCa cells use glucose (sugar) differently than normal cells, substantially increasing lactic acid secretion into the surrounding environment. This supports cancer growth in numerous important ways, including helping PCa avoiding destruction by the patient’s immune system. One critical protein involved […]

Read More